CRISPR is about to make history. Here’s the 5-minute rundown of what to expect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: CRISPR
CRISPR history, biotech struggles, & a big week for deals
How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million…
Morning Rounds: Couples share high blood pressure, and other health stories you should read today
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
STAT Morning Rounds: Six health news stories you need to start your day
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Novartis is building a new radioligand plant in China
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How sickle cell became the first disease treated by CRISPR
Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of…
A new algorithm unveils CRISPR ‘treasure trove’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck cough drug doesn’t pass panel scrutiny
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment
The revolution started in silence. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first…
The return of biotech’s “bump factor” amid an economic downturn
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Key questions (and answers) about the historic approval of a CRISPR-based medicine
History just happened. For the first time, a regulator has cleared a treatment using CRISPR,…
Listen: A CRISPR milestone, algorithms amok, & biotech mixology
Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs…
STAT+: U.K. approves world’s first CRISPR-based medicine, giving greenlight to therapy for sickle cell, thalassemia
LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both…
.jpg)
STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients
Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered…
Your morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Gene editing has had a big week in the spotlight. Here’s what’s going on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Sarepta’s disappointing data put the FDA in a difficult spot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease
The Food and Drug Administration is convening a meeting of outside experts on Tuesday to…
STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show
The Food and Drug Administration said on Friday that it has some safety concerns about…
STAT+: In major test for prime editing, scientists succesfully correct mutations in monkeys
Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called…
Johnson & Johnson antiviral pill for dengue shows early efficacy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol
Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration…
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Live from the 2023 STAT Summit
What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how…
What if there’s no market for a CRISPR cure?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs
When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic?…
In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years
Scientists at a Massachusetts-based biotechnology company and their academic research partners reported Wednesday that an…
To protect chickens from bird flu, researchers try to CRISPR in immunity
LONDON — In this case, it was neither the chicken nor the egg that came…
STAT+: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells
David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching…
STAT+: Sly CAR-T strategy evades ‘fratricide’ problem to aim at all blood cancers
The problem with the plan was fratricide, among other wanton cellular murders. Saar Gill and…
STAT+: Intellia plays down concerns about accidental germline transmission in CRISPR trial
Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in…
STAT+: A yogurt drink instead of a colonoscopy? Study uses engineered bacteria to detect cancer
Dan Worthley, a gastroenterologist and cancer scientist at Colonoscopy Clinic in Brisbane, Australia, does thousands…
STAT+: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid…
Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer’s
When the genome-editing tool CRISPR is thought of as a potential medicine, the targets that…
STAT+: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy
FRANKFURT — Even as other cutting-edge genetic therapies for sickle cell disease move closer to…
STAT+: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys
A defanged form of CRISPR, which doesn’t slice or nick DNA, but rather alters the…
Gene therapy death not caused by CRISPR, investigators confirm
Terry Horgan, the 27-year-old patient who died eight days after receiving a CRISPR therapy custom-built…
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
Jennifer Doudna may be just months away from seeing the first CRISPR-based therapy gain approval,…
STAT+: Early findings in gene therapy death suggest CRISPR was not the cause
In February, four months after the first patient in a designer CRISPR therapy suddenly died,…
STAT+: Researchers devise new strategies to overcome a key CRISPR flaw
DALLAS — It took just three years, after the tool’s invention, for researchers to devise…
STAT+: Setting aside the thorniest issues around CRISPR babies, scientists say embryo-editing research should proceed
LONDON — The Francis Crick Institute is a glimmering chameleon of a building, spanning four…
STAT+: Mice with two fathers and base-edited baby monkeys highlight potential — and limitations — of hereditable gene editing
LONDON — Scientists at this year’s genome editing summit spent Tuesday showing the world just…
With CRISPR cures on horizon, sickle cell patients ask hard questions about who can access them
LONDON — Victoria Gray had come to Nashville, Tenn., from her home in Mississippi for…
‘Make People Better’: The CRISPR babies story you probably don’t know, and how it was filmed in real-time
In May of 2017, Samira Kiani found herself in a San Diego hotel ballroom surrounded…
After three years in prison, ‘CRISPR babies’ scientist is attempting a comeback
He Jiankui, the Chinese biophysicist who created the first gene-edited children, had been quiet since…
STAT+: Editas, facing another setback, halts development on first clinical CRISPR program
Editas Medicine, one of the small handful of original CRISPR companies, announced Thursday it is…
.jpg)
Perfection is too high a bar for CRISPR treatments, says STAT Biomedical Innovation Award winner David Liu
BOSTON — In science journalism, there’s a well-worn technique reporters reach for when they’re interviewing…
STAT+: PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles
Two years ago, researchers at the University of Pennsylvania showed for the first time that…
STAT+: FDA places clinical hold on Verve Therapeutics gene-edting treatment
Verve Therapeutics said Monday that its experimental gene-editing treatment for a common form of heart…